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Abstract
Background: Inhibition of the renin–angiotensin axis can reduce the likelihood of atrial fibrillation 
(AF). However, the effects of angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor 
blockers (ARBs) on thrombogenicity in AF remain incompletely elucidated. Thisretrospective case-control 
study was conducted to evaluate whether the use of ACEI or ARB could reduce the incidence of left atrial 
appendage thrombus (LAAT) and spontaneous echocardiographic contrast (SEC) in patients with AF.
Methods: A total of 199 AF patients who received both transesophageal echocardiogram (TEE) and 
transthoracic echocardiogram (TTE) successively on the same day from 2012 to 2016 were enrolled. 
Left atrial dimension, maximal left atrial volume (LAVmax), left ventricular end-diastolic dimension, 
left ventricular ejection fraction, and the ratio of the early transmitral flow velocity and the early mitral 
annular velocity (E/e’) were determined. Longitudinal LA strain was evaluated using two-dimensional 
speckle tracking imaging at each LA segment. Peak systolic strain was calculated by averaging total 
segments. LAAT, LAA emptying flow velocity (LAAeV) and SEC were evaluated by TEE. Risk factors 
for LAAT and usage of ACEIs or ARBs were recorded.
Results: The incidence of LAAT was 27.6%. Among the patients with renin–angiotensin sys-
tem (RAS) inhibitors, 20.5% were demonstrated to have LAAT, compared with 33.3% in the 
nonuser group (p = 0.044). LA peak systolic strain and LAAeV were significantly increased 
in patients with RAS inhibitors compared to the nonuser group (p = 0.002, p = 0.047, respec-
tively). Patients with LAAT had higher CHA2DS2-VASc scores and evident SEC compared 
with those without LAAT (p = 0.000, p = 0.000, respectively). Usage of ACEIs/ARBs and an-
tiplatelet drugs were frequent in patients with LAAT than in those without LAAT (p = 0.044,  
p = 0.000, respectively). Even after controlling for LAAT-related risk factors (age, body mass index, 
AF type, hypertension, diabetes mellitus, prior stroke or transient ischemic attack, drinking history and 
usage of antiplatelet drugs and LAVmax), use of RAS inhibitors remained significantly associated with 
a lower risk of LAAT (OR = 0.222; 95% CI 0.084–0.585, p = 0.002).
Conclusions: This study shows that RAS inhibitors may be effective in reducing the risk of LAAT in 
patients with AF through atrial reverse remodeling. (Cardiol J 2018; 25, 5: 611–620)
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Introduction
Non-valvular atrial fibrillation (AF) is the 
most common sustained cardiac arrhythmia, in-
creasing the risk of cardio-embolic stroke [1]. 
Left atrial appendage (LAA) is a primary source of 
thromboembolism in stroke patients with AF [2]. 
Transesophageal echocardiography (TEE) can be 
used to identify left atrial appendage thrombus 
(LAAT) and spontaneous echo contrast (SEC). The 
latter is a known precursor of LAAT and systemic 
thromboembolism [3]. 
Many clinical studies have demonstrated 
that left atrial (LA) mechanical remodeling could 
result in thrombus formation in the LAA [4, 5]. 
AF is associated with activation of the renin–an-
giotensin system (RAS) in the atria locally. This 
can lead to both structural and electrophysiologi-
cal remodeling, leading to higher susceptibility 
to arrhythmogenesis [6]. LA peak systolic strain 
measured by two-dimensional (2D) speckle track-
ing, decreased with progressive LA enlargement, is 
inversely related to atrial fibrosis and stiffness. LA 
peak systolic strain shows the potential as a marker 
of LA mechanical and structural remodeling [7].
More recent studies have implicated pro-throm-
botic effects of RAS activation, and inhibition of this 
pathway can reduce the propensity to developing 
AF through reverse remodeling [8, 9]. However, 
whether angiotensin converting enzyme inhibitors 
(ACEIs) or angiotensin II receptor blockers (ARBs) 
can prevent LAAT has not been studied in a clini-
cal context. In this study, it was hypothesized that 
inhibition of RAS can reduce the incidence of LAAT 
in patients with AF through reverse remodeling.
Methods
Patient populations
This is a retrospective study, including all 
consecutive adult patients with AF who under-
went both transthoracic echocardiography (TTE) 
and TEE to determine the presence or absence of 
LAAT from January 1, 2012 to December 31, 2016 
admitted to the Second Hospital of Tianjin Medical 
University. Demographic details, use of RAS inhibi-
tors and risk factors for LAAT on admission were 
recorded and entered into pre-designed spread-
sheets. To minimize subjective judgment and selec-
tion bias, investigators were blinded to outcomes. 
Patients who have never used RAS inhibitors or 
who have used them for less than 3 months were 
assigned to the nonuser group. Patients who had 
used either ACEI or ARB for at least 3 months 
were classified into the user group. The dosage of 
ACEIs or ARBs was adjusted according to blood 
pressure and clinical parameters. Patients who 
were treated with anticoagulation therapy prior 
to the visit were excluded. Patients with previous 
history of LAAT were excluded. Other exclusion 
criteria were significant valvular disease, previous 
valve replacement or reconstruction, intracardiac 
shunting, left ventricular (LV) systolic dysfunction 
defined as LV ejection fraction (LVEF) ≤ 40%, acute 
myocardial infarction, hyperthyroidism, primary 
pulmonary hypertension and respiratory disease. 
Patients who showed inadequate quality of echo-
cardiographic images were also excluded. The 
outcome of the present study was the occurrence 
of LAAT (LAA thrombus and/or sludge).
Echocardiography
Echocardiographic examination was per-
formed using a commercial ultrasound system 
(IE33, Philips Healthcare, Inc.). TEE examination 
was conducted with a 3D matrix array probe (X7-2t, 
carrier frequency 2–7 MHz), whereas TTE ex-
amination was performed using a 1–5 MHz phased 
S5-1 probe. All images were digitally stored and 
analyzed using off-line post processing with QLAB 
Software packages. The following parameters were 
evaluated in standard views with standard tech-
niques [10]: left atrial dimension (LAD), maximal 
left atrial volume (LAVmax), left ventricular end-
diastolic dimension (LVDd), LVEF, and the ratio 
of the early transmitral flow velocity and the early 
mitral annular velocity (E/e’). Tissue Doppler ve-
locities were measured at the septal annuli using 
spectral Doppler tissue imaging. 
An echocardiographer, who was blinded to the 
TTE and clinical data, reviewed all TEE images to 
determine the presence or absence of LAAT [LAAT 
(+) and LAAT(–)], SEC and depressed left atrial 
appendage emptying velocity (LAAeV) (< 40 cm/s) 
by pulsed wave Doppler. LAAT was defined as 
a circumscribed and uniformly echo dense intra-
cavitary mass distinct from the underlying LA or 
LAA endocardium and the pectinate muscles, and 
present in more than one imaging plane [11]. SEC 
was defined as dynamic “smoke-like” echoes with 
the characteristic swirling motion with optimal gain 
setting during the entire cardiac cycle [12]. The 
definition of optimal gain is that images should pro-
vide an adequate endocardial definition to assess 
morphology and motion accurately and quantify 
subtle echocardiographic changes associated with 
SEC. SEC was graded based on Fatkin’s classifica-
tion (1 to 4+) [13]. When dense SEC (grade 3+ 
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or 4+) was present and organized into a dynamic 
and gelatinous, but not solid or well-formed, 
echodensity present throughout the cardiac cycle, 
sludge was reported [14]. LAA sludge was catego-
rized as LAAT [15]. In the present study, it was 
classified LAA sludge as LAAT (Fig. 1). 
Left atrial strain was estimated as the aver-
age of longitudinal strain data from the apical 
4-chamber, 2-chamber and apical long axis views. 
The LA myocardium was divided into 5 regions of 
equal area. Five segments from the apical 4- and 
2-chamber views were analyzed, whereas only 
3 segments in the apical long axis view were analyzed 
because the remaining 2 segments in this view 
are parts of the aortic valve and ascending aorta. 
A total of 13 LA segments were analyzed. The LA 
peak systolic strain during ventricular systole was 
calculated by taking the mean for all 13 segments. 
In patients with AF, echocardiographic parameters 
such as LA strain were calculated as the mean 
values from 5 cardiac cycles. Parameters weree 
carefully measured only in those cycles in which 
the preceding and measured cardiac cycles were 
nearly equivalent.
The study protocol was approved by the Sec-
ond Hospital of Tianjin Medical University Insti-
tutional Review Board.
Statistical analysis
Results were presented as means ± standard 
deviation (SD) for continuous variables and as per-
centages of the total number of patients for categori-
cal variables. All statistical analyses were performed 
using SPSS (version 23.0, SPSS, Chicago, IL, USA). 
Chi-square and the Fisher exact test were used for 
nominal variables. Student t-test was used for com-
parison of continuous variables. Levene’s test was 
used in order to check the homogeneity of variance. 
Equivalent non-parametric tests were used when 
Kolmogorov-Smirnov was in favor of non-normal 
distribution. Results with p < 0.05 were regarded 
as statistically significant. Univariate analysis was 
performed using the c2 test. Variables that were 
significant on univariate logistic regression analysis 
(p < 0.05) were entered into the multivariate analy-
sis. Logistic regression analysis (using the enter 
method) was performed to identify independent 
predictors for LAAT. Risk was expressed as odd-
ratios (OR) with 95% confidence intervals (CI). The 
Hosmer-Lemeshow summary statistic was used to 
assess the goodness-of-fit of the models.
Results
Initially, 429 patients with AF who underwent 
TEE between 2012 and 2016 were identified. After 
assessing them against the exclusion criteria, a total 
of 199 patients were included in the final analysis. 
The average age of the whole cohort was 61.36 ± 
± 9.49 years. 58.8% of the patients were male. 
Patients were categorized into two groups based 
on whether or not they had used ACEIs/ARBs. 
Among these patients, 88 (44.2%) were using RAS 
inhibitors, either ACEIs (40.9%) or ARBs (59.1%). 
Clinical characteristics and echocardiographic 
parameters were compared between the ACEIs/ 
/ARBs user and non-user groups (Table 1). ACEIs/ 
/ARBs users had a higher prevalence of hyperten-
sion than non-users, but other demographic and 
clinical characteristics were comparable between 
these groups. LAAT occurred in 27.6% of the entire 
cohort (55/199 subjects), including 20.5% users of 
ACEIs/ARBs compared to 33.3% in non-users. Us-
ers of ACEIs/ARBs had lower LAVmax, higher LA 
peak systolic strain and higher LAAeV compared to 
A
B
Figure 1. Representative examples of left atrial append-
age thrombus (LAAT) and spontaneous echocardio-
graphic contrast in patients with atrial fibrillation; A. Left 
atrial appendage (LAA) sludge; B. LAAT; AO — aorta; 
LV — left ventricle.
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non-users. No significant differences in LAD, LVDd 
and LVEF were observed between these groups. 
There were 43.2 % (n = 86) patients showed 
SEC. According to the type of findings on TEE, 
the patients were divided into two groups: patients 
with LAAT (LAA thrombus and/or sludge) and pa-
tients without LAAT. Clinical characteristics and 
echocardiographic parameters of the patients with 
or without LAAT are shown in Table 2. Patients 
without LAAT (60.3 ± 9.8 years) were younger 
than patients with LAAT (63.9 ± 7.9 years) (p < 
< 0.05). Body mass index (BMI) and CHA2DS2-
VASc scores were significantly higher in patients 
with LAAT compared to those without LAAT. 
Compared to patients without LAAT, patients with 
LAAT had a higher prevalence of persistent AF, long 
standing persistent AF, hypertension, diabetes mel-
litus, prior stroke or transient ischemic attack (TIA). 
Table 1. Clinical and echocardiography parameters between ACEIs/ARBs users and nonusers group.
Variables ACEIs/ARBs user (n = 88) ACEIs/ARBs nonuser (n = 111) P
Age [years] 62.772 ± 8.184 60.243 ± 10.307 0.055
Age ≥ 65 years 38 (43.1%) 43 (38.7%) 0.526
Male gender 48 (54.5%) 69 (62.2%) 0.278
BMI [kg/m2] 26.295 ± 3.899 25.531 ± 3.087 0.135
AF type: 88 (44.2%) 111 (55.8%) 0.457
Paroxysmal AF 68 (77.3%) 86 (77.5%) 0.973
Persistent AF 18 (20.5%) 19 (17.1%) 0.548
Long standing persistent AF 2 (2.3%) 6 (5.4%) 0.306
Old myocardial infarction 5 (5.7%) 3 (2.7%) 0.470
Vascular disease 4 (4.5%) 6 (5.4%) 1.000
Coronary heart disease 66 (75%) 69 (62.2%) 0.054
Hyperlipidemia 59 (67%) 70 (63.1%) 0.559
Hypertension 77 (87.5%) 54 (48.6%) 0.000
Diabetes mellitus 23 (26.1%) 21 (18.9%) 0.223
Congestive heart failure 6 (6.8%) 4 (3.6%) 0.342
Prior stroke or TIA 10 (11.4%) 11 (9.9%) 0.740
CHA2DS2-VASc score 2.465 ± 1.372 1.828 ± 1.476 0.002
Smoking history 35 (39.8%) 40 (36%) 0.589
Drinking history 21 (23.9%) 19 (17.1%) 0.238
Antiplatelet drugs 50 (56.8%) 50 (45%) 0.099
Statins 43 (48.9%) 52 (46.8%) 0.777
BUN [mmol/L] 5.805 ± 1.552 6.009 ± 1.777 0.395
Serum creatinine [μmol/L] 78.430 ± 25.829 74.205 ± 25.086 0.246
LAD [mm] 39.406 ± 3.883 40.681 ± 6.191 0.078
LAVmax [mL] 50.446 ± 14.604 56.201 ± 23.345 0.035
LVDd [mm] 49.355 ± 6.368 47.939 ± 4.023 0.071
LVEF [%] 57.556 ± 6.438 59.165 ± 6.039 0.074
E/e’ ratio 12.168 ± 4.452 13.857 ± 5.543 0.018
LAAeV [cm/s] 47.415 ± 19.703 41.486 ± 21.613 0.047
LA peak systolic strain [%] 33.756 ± 13.148 27.859 ± 12.688 0.002
SEC 31 (35.2%) 55 (49.5%) 0.043
LAAT 18 (20.5%) 37 (33.3%) 0.044
Data are shown as number (percentage) or mean ± standard deviation. ACEI/ARB — angiotensin converting enzyme inhibitors/angiotensin II 
receptor blockers; AF — atrial fibrillation; BMI — body mass index; BUN — blood urea nitrogen; E/e’ ratio — the ratio of the early transmitral 
flow velocity and the early mitral annular velocity; LA — left atrium; LAAeV — LAA emptying flow velocity; LAAT — left atrial appendage 
thrombus; LAD — left atrial dimension; LAVmax — maximal left atrial volume; LVDd — left ventricular end-diastolic dimension; LVEF — left 
ventricular ejection fraction; SEC — spontaneous echocardiographic contrast; TIA — transient ischemic attack
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The percentage of ACEIs/ARBs users and anti-
platelet drug users were higher in patients without 
LAAT (48.6%) than those with LAAT (32.7%) (p < 
< 0.05). In LAAT patients, 16.4% patients had used 
ACEIs and 16.4% had used ARBs. There were no 
significant differences in LVDd and LVEF between 
the two groups. Lower LA peak systolic strains 
and LAAeV were observed in patients with LAAT. 
Tendency for higher E/e’ ratio, LAD and LAVmax 
was shown in patients with LAAT (Table 2). 
Subgroup analysis demonstrated no signifi-
cant difference in incidence of LAAT between 
Table 2. Clinical and echocardiography parameters of patients with or without LAAT.
Variables LAAT (+) (n = 55) LAAT (–) (n = 144) P 
Age [years] 63.927 ± 7.927 60.381 ± 9.871 0.018
Age ≥ 65 years 31 (56.4%) 50 (34.7%) 0.005
Male gender 36 (65.5%) 81 (56.3%) 0.238
BMI [kg/m2] 26.661 ± 3.464 25.566 ± 3.451 0.047
AF type: 55 (27.6%) 144 (72.4%) 0.000
Paroxysmal AF 28 (50.9%) 126 (87.5%) 0.000
Persistent AF 20 (36.4%) 17 (11.8%) 0.000
Long standing persistent AF 7 (12.7%) 1 (0.7%) 0.001
Old myocardial infarction 2 (3.6%) 6 (4.2%) 1.000
Vascular disease 4 (7.3%) 6 (4.2%) 0.468
Coronary heart disease 41 (74.5%) 94 (65.3%) 0.211
Hyperlipidemia 39 (70.9%) 90 (62.5%) 0.267
Hypertension 45 (81.8%) 86 (59.7%) 0.003
Diabetes mellitus 18 (32.7%) 26 (18.1%) 0.026
Congestive heart failure 5 (9.1%) 5 (3.5%) 0.143
Prior stroke or TIA 19 (34.5%) 2 (1.4%) 0.000
CHA2DS2-VASc score 2.963 ± 1.643 1.784 ± 1.246 0.000
Smoking history 21 (38.2%) 54 (37.5%) 0.929
Drinking history 16 (29.1%) 24 (16.7%) 0.050
ACEI/ARB: 18 (32.7%) 70 (48.6%) 0.044
ACEI 9 (16.4%) 27 (18.8%) 0.696
ARB 9 (16.4%) 43 (29.9%) 0.053
Antiplatelet drugs 15 (27.3%) 85 (59.0%) 0.000
Statins 26 (47.3%) 69 (47.9%) 0.935
BUN [mmol/L] 5.680 ± 1.783 6.010 ± 1.636 0.215
Serum creatinine [μmol/L] 75.827 ± 24.465 76.168 ± 25.885 0.933
SEC 55 (100%) 31 (21.5%) 0.000
LAD [mm] 44.099 ± 5.015 38.597 ± 4.614 0.000
LAVmax [mL] 66.838 ± 21.684 48.622 ± 17.043 0.000
LAVmax ≥ 50 mL 45 (81.8%) 66 (45.8%) 0.000
LVDd [mm] 48.698 ± 5.433 48.514 ± 5.162 0.825
LVEF [%] 57.729 ± 4.996 58.730 ± 6.668 0.254
E:e’ ratio 18.087 ± 3.968 11.209 ± 4.190 0.000
LAAeV [cm/s] 16.887 ± 6.671 54.505 ± 14.033 0.000
LA peak systolic strain [%] 15.565 ± 5.796 36.159 ± 10.499 0.000
Data are shown as number (percentage) or mean ± standard deviation. ACEI/ARB — angiotensin converting enzyme inhibitors/angiotensin II 
receptor blockers; AF — atrial fibrillation; BMI — body mass index; BUN — blood urea nitrogen; E/e’ ratio — the ratio of the early transmitral 
flow velocity and the early mitral annular velocity; LA — left atrium; LAAeV — LAA emptying flow velocity; LAAT — left atrial appendage 
thrombus; LAD — left atrial dimension; LAVmax — maximal left atrial volume; LVDd — left ventricular end-diastolic dimension; LVEF — left 
ventricular ejection fraction; SEC — spontaneous echocardiographic contrast; TIA — transient ischemic attack
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the ACEIs users (25%) and ARBs users group 
(17.3%) (p = 0.379) (Table 3, Fig. 2). Moreover, no 
statistically significant differences in other clinical 
characteristics and echocardiographic parameters 
were observed between the ACEIs and ARBs 
groups (Table 3). Patients with ARBs demonstrated 
significantly less incidence of LAAT compared to 
the nonuser group (p = 0.034) (Fig. 2A). Interest-
ingly, LA peak systolic strain was significantly 
increased both in the ARBs group (p = 0.003) and 
the ACEIs group compared to the non-user group 
(p = 0.048) (Fig. 2B).
Logistic regression analysis was performed to 
identify independent clinical predictors of LAAT 
(Table 4). Univariate analysis demonstrated that 
age, BMI, AF type, hypertension, diabetes mel-
litus, prior stroke or TIA, drinking history, LAV- 
max, usage of ACEIs/ARBs and antiplatelet drugs 
Table 3. Clinical and echocardiographic parameters between patients with ACEIs and ARBs.
Variables ACEIs user (n = 36) ARBs user (n = 52) P 
Age [years] 62.416 ± 7.299 63.019 ± 8.806 0.736
Age ≥ 65 years 13 (36.1%) 25 (48.1%) 0.265
Male gender 19 (52.8%) 29 (55.8%) 0.782
BMI [kg/m2] 26.105 ± 3.645 26.426 ± 4.095 0.287
AF type: 36 (40.9%) 52 (59.1%) 0.341
Paroxysmal AF 25 (69.4%) 43 (82.7%) 0.145
Persistent AF 10 (27.8%) 8 (15.4%) 0.156
Long standing persistent AF 1 (2.8%) 1 (1.9%) 1.000
Medication time [months] 15.916 ± 13.296 14.067 ± 10.558 0.470
Old myocardial infarction 1 (2.8%) 4 (7.7%) 0.645
Vascular disease 2 (5.6%) 2 (3.8%) 1.000
Coronary heart disease 30 (83.3%) 36 (69.2%) 0.133
Hyperlipidemia 21 (58.3%) 38 (73.1%) 0.148
Hypertension 31 (86.1%) 46 (88.5%) 0.754
Diabetes mellitus 6 (16.7%) 17 (32.7%) 0.093
Congestive heart failure 3 (8.3%) 3 (5.8%) 0.685
Prior stroke or TIA 4 (11.1%) 6 (11.5%) 1.000
CHA2DS2-VASc score 2.277 ± 1.365 2.596 ± 1.375 0.287
Smoking history 13 (36.1%) 22 (42.3%) 0.559
Drinking history 8 (22.2%) 13 (25%) 0.764
Antiplatelet drugs 21 (58.3%) 29 (55.8%) 0.811
Statins 16 (44.4%) 27 (51.9%) 0.490
BUN [mmol/L] 6.122 ± 1.578 5.586 ± 1.510 0.112
Serum creatinine [μmol/L] 75.847 ± 20.301 80.219 ± 29.107 0.438
LAD [mm] 39.561 ± 3.906 39.299 ± 3.902 0.757
LAVmax [mL] 50.538 ± 15.848 50.382 ± 13.837 0.961
LVDd [mm] 49.846 ± 6.033 49.016 ± +6.626 0.551
LVEF [%] 58.649 ± 6.646 56.799 ± 6.242 0.187
E/e’ ratio 12.436 ± 3.968 11.982 ± 4.787 0.641
LAAeV [cm/s] 46.405 ± 20.706 48.115 ± 19.151 0.691
LA peak systolic strain [%] 32.822 ± 13.730 34.403 ± 12.826 0.582
SEC 15 (41.7%) 16 (30.8%) 0.293
LAAT 9 (25%) 9 (17.3%) 0.379
Data are shown as number (percentage) or mean ± standard deviation. ACEI/ARB — angiotensin converting enzyme inhibitors/angiotensin II 
receptor blockers; AF — atrial fibrillation; BMI — body mass index; BUN — blood urea nitrogen; E/e’ ratio — the ratio of the early transmitral 
flow velocity and the early mitral annular velocity; LA — left atrium; LAAeV — LAA emptying flow velocity; LAAT — left atrial appendage 
thrombus; LAD — left atrial dimension; LAVmax — maximal left atrial volume; LVDd — left ventricular end-diastolic dimension; LVEF — left 
ventricular ejection fraction; SEC — spontaneous echocardiographic contrast; TIA — transient ischemic attack
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were significantly associated with LAAT. However, 
only the categories of AF type, age ≥ 65 years, hy-
pertension, prior stroke or TIA, LAVmax ≥ 50 mL, 
usage of ACEIs/ARBs and antiplatelet drugs were 
associated with LAAT following multivariate ad-
justments (Table 4). After controlling for the factors 
related to LAAT, the use of RAS inhibitors re-
mained significantly associated with a lower risk of 
LAAT incidence (OR = 0.222; 95% CI 0.084–0.585, 
p = 0.002) (Table 4).
Discussion
Major findings
The major finding of the present study is that 
the use of RAS inhibitors was associated with 
a lower incidence of LAAT in patients with AF. 
According to available literature, this is the first 
clinical study that has assessed the antithrombotic 
property of RAS inhibitors with respect to LAAT 
prevention using echocardiography.
Roles of RAS in atrial remodeling  
and LAA thrombus
Renin–angiotensin system activation is known 
to play a critical role in structural and electrophysi-
ological remodeling in the atrial myocardium, which 
can increase the susceptibility to arrhythmia and 
the development of AF [16]. Besides, adverse 
hemodynamic effects, activation of multiple cell 
signaling cascades facilitates increased intracel-
lular calcium, hypertrophy, apoptosis, cytokine 
Figure 2. Left atrial appendage thrombus (LAAT) incidence and left atrium (LA) peak systolic strain in patients 
with angiotensin converting enzyme inhibitors (ACEIs) angiotensin II receptor blockers (ARBs) and without 
ACEIs/ARBs; A. LAAT incidence in patients with ACEIs, ARBs and nonuse; B. LA peak systolic strain in patients 
with ACEIs, ARBs and nonuser; *p < 0.05; #p > 0.05.
Table 4. Multivariate logistic regression analyses for left atrial appendage thrombus. 
Variables Odds ratio 95% CI P 
Age ≥ 65 years 2.166 0.906–5.178 0.082
LAVmax ≥ 50 mL 3.491 1.343–9.074 0.010
Body mass index 1.012 0.893–1.148 0.848
AF type 0.093
Hypertension 4.377 1.601–11.969 0.004
Diabetes mellitus 1.917 0.636–5.775 0.248
Prior stroke or TIA 17.342 2.937–102.412 0.002
Drinking history 2.011 0.686–5.892 0.203
ACEI/ARB 0.222 0.084–0.585 0.002
Antiplatelet drugs 0.370 0.151–0.905 0.029
ACEI/ARB — angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; AF — atrial fibrillation; CI — confidence interval;  
LAVmax — maximal left atrial volume; TIA — transient ischemic attack
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release, inflammation, oxidative stress and expres-
sion of growth-related factors that also stimulate 
fibrosis, possible modulation of ion channel and 
gap-junction dynamics. Electrical contractile and 
structural remodeling are dominant factors for AF 
genesis. Fibrosis is part of the structural remod-
eling process [17], which can negatively impact 
on the mechanical function of the atria, in turn 
predisposing to thrombus formation in the LAA 
[4, 5]. These findings seem physiologically reason-
able, as atrial emptying is attenuated with impaired 
LA function and elevated LA fibrosis, causing atrial 
blood stasis and thrombus formation [18].
Left atrial peak systolic strain  
and the risk of LAA thrombus
The presence of SEC or reduced LAA empty-
ing velocity (LAAeV), as measured using TEE, 
has been shown to be helpful in detecting LAA 
dysfunction [3] and provides useful markers for 
stratification of thromboembolic risk in patients 
with AF [4]. 2D speckle-tracking strain imaging is 
a novel method for quantitative real-time assessment 
of regional myocardial deformation which uses 
tracking of acoustic speckles or kernels instead of 
Doppler myocardial velocities [19]. Recently, this 
technique has been recommended for the quantifi-
cation of LA myocardial deformation and indicated 
to evaluate the atrial function accurately during 
the different phases of the cardiac cycle [20]. LA 
mechanical function can be broadly divided into 
reservoir, conduit and pump function. The burden 
of LA fibrosis, analyzed by magnetic resonance 
imaging, displays an inverse correlation with LA 
strain evaluated by 2D speckle tracking [7]. LA 
reverse remodeling could be predicted indepen-
dently by LA systolic strain [21]. These results 
indicated that LA peak systolic strain is correlated 
with mechanical and structural remodeling of the 
LA and is helpful to assess LA reservoir function 
[22]. One study showed that LA peak systolic 
strain was dramatically correlated with LAAeV in 
patients with AF [23]. LA peak systolic strain was 
decreased with LA enlargement and increasing age. 
Decreasing LA peak systolic strain (normal value 
42.2 ± 6.1%) was considered as a reliable marker 
of LAA dysfunction and thrombus risk in patients 
with AF [23, 24]. 
Maximal left atrial volume  
and the risk of LAA thrombus
Enlargement of LA is associated with aging, 
hypertension, and LV diastolic dysfunction, and is 
an independent factor of AF [25]. Conversely, AF 
itself can enhance LA remodeling and higher AF 
burden can also lead to LA enlargement [25]. An 
enlarged LA could be a predictive factor for the 
occurrence of stroke [26]. A previous study has 
shown that LA volume was correlated with LAA 
maximal area, which was an independent predictor 
for LAA thrombus formation [27]. In the present 
study, the maximum LA volume (LAVmax) was 
found to be an independent risk factor for LAAT 
even after adjusting for other factors such as ag-
ing and hypertension. It suggested that dilation of 
left cardiac chambers offered a suitable terrain for 
thrombus formation.
Roles of RAS inhibitors in atrial  
remodeling and thrombus formation
Among the components of renin–angioten-
sin–aldosterone system (RAAS), ACE and angio-
tensin II are known to contribute to atrial fibrotic 
remodeling during AF. RAAS inhibitors containing 
ACEIs or ARBs are involved in upstream therapy. 
They can reduce atrial stretch, fibrosis and re-
verse remodeling process via RAAS inhibition 
and may lower the development of AF [28]. The 
present study demonstrated decreased LA peak 
systolic strains in LAAT patients. Patients who 
used ACEIs/ARBs had significantly greater LA 
peak systolic strains and lesser incidence of LAAT 
compared to those who didn’t use ACEIs/ARBs. 
Multivariate logistic regression analysis showed 
that RAS inhibitors were independently associated 
with lower risk of LAAT.
Differences between the effects of  
ARBs and ACEIs on LAA thrombus
Subgroup analysis demonstrated no significant 
differences in clinical characteristics, echocar-
diographic parameters and incidence of LAAT 
between patients on ACEIs and those on ARBs. 
LAAT incidence was significantly reduced in ARBs 
group, and tended to be reduced in ACEIs group 
when compared with non-user group. However, 
it was not significantly different between ARBs 
vs. ACEIs groups. Interestingly, LA peak systolic 
strains in patients with ACEIs or ARBs were signif-
icantly increased compared to the non-user group. 
Several studies have reported antiplatelet, antico-
agulant and pro-fibrinolytic effects of ARBs [29– 
–31]. Moreover, angiotensin II AT-1-type receptor 
antagonists can reduce TxA2-dependent activation 
independent of angiotensin II involvement. Indeed, 
inhibitory effects on platelet activation by some 
ARBs such as losartan have been reported to be 
as high as those of acetylsalicylic acid (ASA) [32]. 
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ARBs can decrease the expression of the arterial 
adhesion molecule, vascular cell adhesion protein-1 
(VCAM-1), and endothelial fibrosis, both of which 
are implicated in the thrombogenic process [33, 
34]. In the present study, the use of ARBs might in-
deed have greater direct antiplatelet, anticoagulant 
and other reverse-remodeling actions compared 
to ACEIs, and thus contributed to a lower the 
incidence of LAAT.
Results herein indicate that ACEIs and ARBs 
can reduce LAAT risk. In the present study, patients 
who have been treated with anticoagulation therapy 
were excluded. However, some other drugs have 
been considered to have an effect on LAAT. For ex-
ample, the SPAF-1 trial shows benefit for ASA alone 
in preventing stroke among patients with AF. For 
primary prevention, ASA use was associated with 
a 19% reduction in stroke incidence with an abso-
lute risk reduction of 0.8% per year. For secondary 
prevention among those with TIA or strokes, ASA 
use was associated with an absolute risk reduction 
of 2.5% per year [35, 36]. Moreover, several sys-
tematic reviews have demonstrated the beneficial 
effects of statin therapy in preventing AF [37, 
38]. In the present study, antiplatelet drugs were 
an independent predictor of LAAT (OR = 0.370; 
95% CI 0.151–0.905; p = 0.029). However, there 
was no interaction between the usage of ACEIs/ 
/ARBs and antiplatelet agents. It is notable that 
even after adjusting for dosage of antiplatelet drug, 
the relationship between ACEIs/ARBs users and 
the risk of LAAT was not significantly altered. 
However, statin use was not significantly corre-
lated with the incidence of LAAT.
Limitations of the study
There are several intrinsic limitations of 
this study which should be noted. Firstly, it is 
a hospital-based retrospective study. Secondly, 
the sample size was small with a limited number 
of events. Thirdly, ascertainment bias was a pos-
sibility. Although medication reconciliation forms 
were used to assess the duration of ACEIs/ARBs 
usage, but this may not reflect medication adher-
ence. Fourthly,  there was an inability to assess the 
dosage-related effects in this study, partly due to 
frequent dosage alterations during the course of the 
study. Finally, blood coagulation-related parameters 
were not recorded.
Conclusions
In summary, this study showed that the use of 
RAS inhibitors might be associated with reverse 
LA remodeling and a reduction in the risk of LAAT. 
Larger, prospective studies are needed to ascer-
tain the benefit of RAS inhibition in reducing the 
incidence of LAAT.
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